The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Review article: hepatitis B core‐related antigen (HB crAg): an emerging marker for chronic hepatitis B virus infection
Open accessAbstract
Summary: Background: Chronic hepatitis B (CHB) cannot be completely eradicated due to the presence of covalently closed circular DNA (ccc DNA) in the nuclei of infected hepatocytes. While quantification of intrahepatic ccc DNA requires liver biopsies, serological markers can be non‐invasive alternatives to reflect intrahepatic viral replicative activity. Recently, hepatitis B core‐related antigen (HB crAg) has been advocated as a novel serum marker for disease monitoring and prognostication of CHB. Aim: To examine the virological aspect and clinical application of HB crAg with respect to the natural history and treatment of CHB. Methods: We reviewed all papers published in the PubMed journal list and abstracts from major international meetings that included the keyword “HB crAg” or “hepatitis B core‐related antigen” until March 2017. Selected studies were compared and summarised on the basis of existing theories, as well as the authors’ experience. Results: HB crAg exhibited good correlation with intrahepatic (ih) ccc DNA, ih total hepatitis B virus (HBV) DNA, serum HBV DNA and to a lesser extent HBV surface antigen (HB sAg). In situations where serum HBV DNA levels become undetectable or HB sAg loss is achieved, HB crAg can still be detectable. This marker is helpful in differentiation of HB eAg‐negative chronic hepatitis from HB eAg‐negative chronic infection, predicting spontaneous or treatment‐induced HB eAg seroconversion, sustained response to nucleos(t)ide analogue (NA), risk of HBV reactivation in occult HBV infection under immunosuppressive therapies, and risk of hepatocellular carcinoma (HCC) development as well as post‐operative HCC recurrence. Conclusions: HB crAg is a potential surrogate marker of ccc DNA. It may soon become a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Cited by
Yuen, M.-F., Chen, D.-S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C.-L. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.35 · Cited by 814
Self-citationCornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L. Y., Chang, K.-M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.003 · Cited by 366
Metadata
- Authors
- Mak, L. ‐., Wong, D. K. ‐., Cheung, K. ‐., Seto, W. ‐., Lai, C. ‐., & Yuen, M. ‐.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-10-16
- Volume
- 47
- Issue
- 1
- Pages
- 43-54
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2766670674
- Cited by
- 217
- References
- 1
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review article: hepatitis B core‐related antigen (HB crAg): an emerging marker for chronic hepatitis B virus infection. https://app.cochat.ai/papers/10.1111/apt.14376
- The paper
- Mak, L. ‐., Wong, D. K. ‐., Cheung, K. ‐., Seto, W. ‐., Lai, C. ‐., & Yuen, M. ‐. (2018). Review article: hepatitis B core‐related antigen (HB crAg): an emerging marker for chronic hepatitis B virus infection. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.14376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.